Sitagliptin myostatin

Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, has been shown to exert anti-inflammatory effects and potentially improve muscle health. Studies indicate that sitagliptin can inhibit myostatin expression, a protein that negatively regulates muscle growth, and increase MyoD expression, a transcription factor involved in muscle development. This suggests that sitagliptin may have therapeutic effects on muscle atrophy or sarcopenia, conditions characterized by muscle loss.
Here's a more detailed explanation:
Sitagliptin and Myostatin

Sitagliptin is an antidiabetic medication that works by inhibiting DPP-4, an enzyme that breaks down incretins like GLP-1 and GIP. These incretins stimulate insulin release and suppress glucagon secretion, leading to improved blood sugar control. Research has also shown that sitagliptin can inhibit myostatin, a protein that plays a crucial role in regulating muscle growth.
Myostatin's Role

Myostatin is a protein that acts as a muscle growth inhibitor. By inhibiting myostatin, sitagliptin may promote muscle hypertrophy (growth) and potentially improve muscle function.
MyoD Expression:
MyoD is a transcription factor that plays a key role in muscle development. Studies have shown that sitagliptin can increase MyoD expression, further supporting its potential role in muscle health.
Therapeutic Potential:
The ability of sitagliptin to inhibit myostatin and increase MyoD expression suggests that it may have therapeutic potential in conditions like muscle atrophy (loss of muscle mass) or sarcopenia (age-related muscle loss).
In summary, while primarily used for diabetes, sitagliptin's actions on myostatin and MyoD expression suggest it may also have beneficial effects on muscle health, potentially offering a way to combat muscle loss in certain conditions.

The proposed mechanism, DPP-4 inhibition leading to GDF-8 reduction via GLP-1 pathway modulation, is theoretically plausible but the in vivo evidence is weak. Studies cited are generally in sarcopenic or diabetic populations. In a healthy resistance-trained individual I would not expect meaningful myostatin reduction from therapeutic sitagliptin dosing.

The proposed pathway: sitagliptin inhibits DPP-4, GLP-1 and GIP accumulate, increased IGF-1 signalling suppresses SMAD2 and SMAD3 phosphorylation downstream of ActRIIB, reducing myostatin gene expression. The mechanistic logic is coherent but the magnitude of effect in healthy non-diabetic subjects is unknown. Interesting hypothesis, insufficient evidence to justify the compound solely for this purpose.

The DPP-4 inhibitor research is interesting but doses used in studies are therapeutic range, not supraphysiological. Do not expect dramatic body composition changes. Keep lifting heavy and eating to support your goals.

The research on DPP-4 inhibitors and myostatin is still early but the mechanism makes sense. We have been using metformin for years for similar metabolic reasons. Worth watching as the data develops.

I added sitagliptin 100mg daily to my current cycle running test E 400mg and primo 400mg. After 8 weeks body composition improvement appears enhanced compared to my previous equivalent cycle without it. Difficult to isolate the single variable but the mechanism is plausible. DPP-4 inhibition increases active GLP-1 which has muscle-sparing effects. I will complete the full 16-week cycle and compare final measurements against previous data.

The sitagliptin and myostatin data is preliminary but mechanistically plausible. DPP-4 inhibition has downstream effects on follistatin related proteins that modulate myostatin. Whether the effect size is clinically meaningful in a well-trained individual is the key question - most studies showing benefit are in sarcopenic or diabetic populations where baseline myostatin activity is significantly elevated. Worth tracking as more data comes out.